The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.

The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient ...

The FDA has approved the use of Spravato, an antidepressant nasal spray, as a standalone treatment for depression in the U.S. Sue Varma discusses why she supports the use of the drug and how it may ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...

Approval of Spravato, granted following FDA priority review ... the mechanism by which esketamine exerts its antidepressant effect is unknown. In an effort to ensure the safe and appropriate ...

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.

The decision builds on previous FDA approval for the drug’s treatment when combined with additional oral antidepressants. While Spravato’s underlying mechanisms remain unclear and only be ...

is the first and only monotherapy for adults with major depressive disorder who have had inadequate response to at least two oral antidepressants. The FDA has approved a supplemental new drug ...

However, the FDA approval for Spravato is based on a phase ... clinical data on Spravato’s use in combination with oral antidepressants. As per Martin, demonstrates “not only rapid symptom ...